Mumbai, June 24 -- Biocon Biologics Limited, a fully integrated global biosimilars company, on Tuesday said that it has partnered with the National Cancer Society of Malaysia (NCSM), a prominent not-for-profit cancer organization, to launch a Patient Assistance Program (PAP) in Malaysia aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia.
Biocon Biologics will provide quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim and Bevacizumab, to NCSM, which will manage patient enrolment
and medicine supply as part of its healthcare services.
This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance c...